Donepezil
Treatment for Vascular Dementia
Typical Dosage: 5-10 mg daily
Effectiveness
65%
Safety Score
60%
Clinical Trials
9
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
5-10 mg daily
Time to Effect
1-3 months
Treatment Duration
Lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
70%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$500
Side Effect Mgmt:$100
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$2,000
Donepezil Outcomes
for Vascular Dementia
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+35%
Common Side Effects
Nausea
+15%
Diarrhea
+10%
Insomnia
+10%
Vomiting
+5%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
6 completed trials for Donepezil in Vascular Dementia
Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia
NCT00165763COMPLETEDPHASE4
36 participants
INTERVENTIONAL
Quezon, Philippines +1 more
Started: Sep 1, 2005
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease
NCT00165737COMPLETEDPHASE3
974 participants
INTERVENTIONAL
Hot Springs, United States +4 more
Started: Mar 1, 2003
Non-Interventional Study With Aricept® Evess
NCT00889603COMPLETED
370 participants
OBSERVATIONAL
Bacau, Romania +11 more
Started: May 1, 2009
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
NCT02453932COMPLETEDPHASE3
543 participants
INTERVENTIONAL
Beijing, China
Started: Oct 1, 2013
Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease
NCT00188812COMPLETEDPHASE3
INTERVENTIONAL
Toronto, Canada
Started: May 1, 2004
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
NCT01872598COMPLETEDPHASE3
721 participants
INTERVENTIONAL
Varna, Bulgaria +5 more
Started: Jan 1, 2012